ondary acute myeloid leukemias (AML) has been described in hematologic relapse were compared to those obtained at initial children previously treated for ALL with regimens containing diagnosis in 128 patients (69 children and 59 adults) with acute teniposide on a twice weekly schedule. 8,9 It is, therefore, use- files at relapse and at diagnosis was not carried out in 14 in infants and adults compared to children. Several studies patients who presented at relapse with Ͻ30% blasts in the have focused on the immunophenotype of the leukemic popubone marrow aspirate and in 67 patients because of an incomlation at the time of relapse compared to that observed at diagplete immunophenotype performed at the time of presentation nosis. [1] [2] [3] [4][5][6][7] Although in the majority of cases a modification in and/or at 1st relapse. A total of 128 patients were evaluable, the phenotypic profile of the neoplastic clone does not occur, including 69 children (median age 7 years, 0.2-14.8) and 59 in a notable number of B and T lineage ALL immunophenoadults (median age 30.8 years, 15-67). Median duration of 1st typic changes have been recorded. In most cases, these are CR was 16 months (range 2-80), shorter than 1 year in 51 represented by a loss of differentiation antigens, suggesting patients and longer in 77. All patients were treated at diagthat relapses may originate from a more undifferentiated subnosis and at relapse with anti-ALL chemotherapy regimens in clone of leukemic blasts. In childhood ALL, an overall change order to achieve CR and long-term event-free survival (EFS). in the immunophenotype at relapse does not seem to influSince over the years different treatment protocols were ence the response to salvage therapy, but relapses of T lineage employed these have been grouped under two major categor-ALL have been associated with a worse outcome compared ies: standard and intensive. Standard treatment schemes to B lineage ALL. 5 included a four drug induction (anthracycline, vincristine, L-A phenotypic change at relapse does not necessarily imply asparaginase, prednisone), followed by consolidation, reinthat a new leukemic clone has emerged. Cytogenetic and duction and maintenance. Intensive treatments included an gene rearrangement studies indicate that recurrence of disease induction phase with either high-dose cytosine arabinoside generally involves the same clone. [4][5][6] A high frequency of seccombined with an anthracycline or a prolonged eight drug combination (BFM-like induction), followed by intensive consolidation and short but intensive reinduction courses and maintenance. Both standard and intensive therapies included
Response to treatment was evaluable in 482 patients. The 32 unevaluable cases included 18 referred only for diagnosis and 14 that were Introduction treated only with palliative therapy. 443 patients achieved a complete remission (CR) (92%) and 209 of these subsequently Relapses of acute lymphoblastic leukemia (ALL) occur with relapsed. A comparison between the immunophenotypic prodifferent frequencies according to patients' age, being higher files at relapse and at diagnosis was not carried out in 14 in infants and adults compared to children. Several studies patients who presented at relapse with Ͻ30% blasts in the have focused on the immunophenotype of the leukemic popubone marrow aspirate and in 67 patients because of an incomlation at the time of relapse compared to that observed at diagplete immunophenotype performed at the time of presentation nosis. [1] [2] [3] [4] [5] [6] [7] Although in the majority of cases a modification in and/or at 1st relapse. A total of 128 patients were evaluable, the phenotypic profile of the neoplastic clone does not occur, including 69 children (median age 7 years, 0.2-14.8) and 59 in a notable number of B and T lineage ALL immunophenoadults (median age 30.8 years, 15-67). Median duration of 1st typic changes have been recorded. In most cases, these are CR was 16 months (range 2-80), shorter than 1 year in 51 represented by a loss of differentiation antigens, suggesting patients and longer in 77. All patients were treated at diagthat relapses may originate from a more undifferentiated subnosis and at relapse with anti-ALL chemotherapy regimens in clone of leukemic blasts. In childhood ALL, an overall change order to achieve CR and long-term event-free survival (EFS). in the immunophenotype at relapse does not seem to influSince over the years different treatment protocols were ence the response to salvage therapy, but relapses of T lineage employed these have been grouped under two major categor-ALL have been associated with a worse outcome compared ies: standard and intensive. Standard treatment schemes to B lineage ALL. 5 included a four drug induction (anthracycline, vincristine, L-A phenotypic change at relapse does not necessarily imply asparaginase, prednisone), followed by consolidation, reinthat a new leukemic clone has emerged. Cytogenetic and duction and maintenance. Intensive treatments included an gene rearrangement studies indicate that recurrence of disease induction phase with either high-dose cytosine arabinoside generally involves the same clone.
4-6 A high frequency of seccombined with an anthracycline or a prolonged eight drug combination (BFM-like induction), followed by intensive consolidation and short but intensive reinduction courses and maintenance. Both standard and intensive therapies included Leukemic blasts were obtained from bone marrow aspirate or peripheral blood by density gradient centrifugation (Lymphoprep, Nycomed Pharma, Oslo, Norway) followed by lowed by epifluorescence microscope analysis (Axioplan; Zeiss). Expression in over 20% of blasts was required to define antigen positivity, with the exception of CD34 and TdT in Statistics which the positivity cut-off was 10%. Since 1988, a double staining was performed in selected cases by direct 2 analysis was used to correlate the following variables: immunophenotype (B lineage ALL vs T lineage ALL) at diagimmunofluorescence with either FITC-or PE-conjugated MoAb. Immunologic cell marker studies allowed the identifinosis and at 1st relapse, duration of 1st CR (Ͻ1 year vs Ͼ1 year), inclusion of teniposide in the treatment preceding 1st cation of nine diagnostic groups of ALL: five of B lineage (null, early pre-B, common, pre-B and mature-B) and four of T linrelapse (yes vs no), a change in the immunophenotypic diagnostic group at 1st relapse to a less or to a more differentiated eage (pre-T, early-T, cortical thymic and mature T) ( Table 2) . Furthermore, we defined as My+ALL cases which fulfilled the phenotype (yes vs no), a change in the expression of one or more antigens at relapse (yes vs no), age at diagnosis (Ͻ15 above described diagnostic criteria and which also expressed CD13 and/or CD33, with either CD19 or CD7 on more than years vs Ͼ15 years), achievement of 2nd CR (yes vs no).
Continuous complete remission duration after relapse is 20% of blasts. Table 4 Change in antigen expression at relapse defined as the time from 2nd CR to relapse or to the last observation in 2nd CR. EFS after relapse is defined as the time from relapsed cases included in the study, are illustrated in Table 3 . Eighty-three cases were not classified at diagnosis because of which myeloid markers CD13 and CD33 were not evaluated. The incidence of My+ALL in our group of ALL at diagnosis had a higher probability of changing immunophenotype at relapse compared to B lineage ALL in all age groups, the difference being equally significant in children and in adults changes is shown in Table 4 . The CD10 antigen was acquired (P = 0.03). Phenotypic changes occurred in all five cases of at relapse in seven cases (five B lineage and two T lineage My+ALL. The frequency of individual antigen expression ALL) and lost in eight (seven B lineage ALL and one T lineage). By contrast, TdT, HLA-DR, CD19, Smlg and CD7 rarely changed at relapse. The stem cell antigen CD34 was tested at diagnosis and at 1st relapse in 40 patients. It was positive at B0  B1  B2 B3 B4 T0 T1 T2 T3 Total  Pre-T  15  12  8  2  Early-T  16  13  9  7  Diagnosis  B0  0  0  0  0 0  0  0  0 0  0  Cortical thymic-T  36  34  16  6  Mature-T  19  17  11  10  B1  0  10  3 Includes 12 cases negative for CD7 and for CD19 in which CD13 B0, null ALL; B1, early pre-B ALL; B2, common ALL; B3, pre-B ALL; B4, mature B ALL; T0, pre-T ALL; T1, early-T ALL; T2, cortical thyand CD33 were not evaluated. CR, complete remission. mic T-ALL; T3, mature T-ALL. (P = 0.0003). Duration of 1st CR was correlated to the c As evaluated at first diagnosis.
immunophenotype since it was shorter than 1 year in 29% of B lineage ALL, in 58% of T (P = 0.02) and in 3/5 My+ALL. Comparing the immunophenotype at first hematological relapse to
Children had a slightly higher probability of achieving a 2nd
that at diagnosis. CR, complete remission; ALL, acute lymphoblastic leukemia; HR, CR compared to adults (74 vs 52%, P = 0.04). According to hazard ratio; NS, P value Ͼ0.10; BMT, allogeneic bone marrow our classification criteria of anti-leukemic therapies, no sigtransplantation; My+ALL, myeloid antigens positive ALL; NE, not nificant influence of both first and second line treatment intenevaluable because of short follow-up; →UNDIFF, shift to a less difsity on the rate of 2nd CR and EFS curve was noted. However patients treated with allogeneic BMT had a slightly better EFS curve compared to the 67 patients treated with chemotherapy ± autologous BMT (not significant). to T lineage ALL (P = 0.02); this difference remained significant with the exclusion of patients treated with allogeneic T lineage ALL had a slightly lower 2nd CR rate (60 vs 65%, not significant) and a worse EFS curve compared to B lineage BMT after 2nd CR (P = 0.002). As shown in Table 6 , we did not observe statistically significant prognostic differences ALL (P = 0.03). This observation is sustained by the significantly lower risk of 2nd relapse of B lineage ALL compared comparing: (1) patients in whom a phenotypic modification was observed at relapse or not; (2) patients shifting to a more exception of one case that lost the CD20 antigen. 6 In our series, phenotypic changes were observed in 38% of B lineage undifferentiated immunophenotype or not, (3) patients with B lineage ALL acquiring myeloid antigens at relapse or not. The ALL, with a loss of acquisition of the CD10 antigen in 12% of the cases. This change occurred both in children and in acquisition or loss of each one of the antigens tested did not influence significantly the outcome (data not shown).
adults. CD34 was frequently lost or acquired at relapse both in B and in T lineage ALL, but its modification did not parallel Of the different immunologic patterns at diagnosis, the more undifferentiated phenotypes had a worse outcome. Early other shifts towards a more or a less differentiated immunophenotype. The appearance of myeloid antigens was observed pre-B ALL had a 2nd CR rate of 28% compared to the more differentiated subgroups of common ALL (70%) and pre-B ALL at relapse in 12% of B lineage ALL (and in no T lineage ALL) and was not associated with age at diagnosis. (77%) (P = 0.009). Similarly, pre-T ALL plus early-T ALL had a 44% rate of 2nd CR compared to 66% for cortical thymic A high frequency of secondary AML has been reported in children receiving treatment with teniposide for a diagnosis of T-ALL and to 70% for mature T-ALL (not significant). The ALL-1 gene rearrangement was found in 1/5 studied cases with ALL. 8 In our series, teniposide was given before 1st relapse only in a minority of children, but the majority of adults early pre-B ALL (Dr G Cimino, personal communication). Since a shift to a more or to a less differentiated received this drug as part of the initial therapy. No secondary AML has been recorded, nor did teniposide affect the immunophenotype was observed at relapse in 34 patients, it appears that grouping patients according to the immunoexpression of myeloid antigens at relapse. The relatively small number of patients treated with teniposide (nine children and phenotype at relapse did not bear any prognostic relevance.
Patients age (Ͻ15 years vs Ͼ15 years), duration of 1st CR 47 adults) and their short median duration of 1st CR (12 months) may play a role in the lack of secondary AML (Ͻ1 year vs Ͼ1 year), lineage affiliation (B vs T) and grade of differentiation (null + early pre-B + pre-T + early-T vs common observed in our study.
The phenotypic changes at relapse determined a different + pre-B + cortical thymic T + mature T) were analyzed by a multivariate method to recognize independent prognostic intralineage subtype classification in 23% of B progenitor ALL and in 40% of T lineage ALL, with more relapsed cases factors for EFS. Duration of 1st CR (P = 0.005, hazard ratio = 0.555) and grade of differentiation (P = 0.033, hazard expressing a less differentiated immunophenotype. Thus, an overall change in subgroup classification was recorded in ratio = 0.569) had independent and statistically significant prognostic value in all age groups, while lineage affiliation 26.5% of ALL cases analyzed. In view of the different therapeutic protocols implemented lost its prognostic value.
over a follow-up period of 13 years, it was difficult to correlate the pattern of immunophenotypic changes at relapse with any specific treatment scheme. However, treatment intensity, Discussion defined according to the myelosuppressive activity of antileukemic regimens, failed to influence significantly the phenoIn the present study, the immunophenotype at 1st hematological relapse of 128 consecutive patients with ALL observed type changes nor did it affect the outcome of salvage therapy after 1st relapse. at our Institution since January 1984 was compared to that recorded at diagnosis. These cases represent the majority of Flow cytometric analysis of bone marrow cells with particular antigenic combinations has been proposed as a method the total number of ALL in 1st hematological relapse observed during this period of time. Each case was classified, according to detect minimal residual disease (MRD) and to predict relapse in acute leukemias. 17 A phenotypic switch at relapse to lineage and to the differentiative step, into one of nine diagnostic groups (Table 3) . Our series includes a significant numin ALL may represent an obstacle to the efficacy of this method in monitoring the disease during remission. As ber of adults with ALL (n = 59) and of T lineage ALL (n = 25), two groups of patients in whom large studies on the immunoobserved in our study, the co-expression of either myeloid + B markers, or CD34 + B markers, or CD34 + T markers phenotype at the time of 1st relapse have so far not been reported. In addition, we studied the expression of the stem observed at diagnosis can disappear at relapse, thus representing a potential source of error in detecting MRD in a cell antigen CD34 and of the two most relevant myeloid antigens, CD13 and CD33. significant proportion of My+ALL and CD34 + ALL cases. The surface expression of the myeloid antigen CD13 on leukemic The incidence of immunophenotypic changes in T lineage ALL was 80%, significantly higher than in B lineage ALL B precursor ALL has been found to be modulated by in vitro culture with bone marrow-derived stromal layers. 18 These (38%), both in children and in adults. Acquisitions or losses have been recorded practically for all antigens tested, authors speculate that CD13 expression could change during sample transportation to a referral laboratory. This cannot although changes at relapse more frequently involved CD10, CD20, cylgM, CD13 and CD33 in B lineage ALL and CD5, explain our results, since we performed immunophenotypic studies within a few hours from sample drawing. T-ALL has CD2, CD1a, CD4, CD8 and surface CD3 in T lineage ALL. A phenotype shift of membrane marker expression has been been reported to be particularly suitable for MRD studies using immunological techniques. 17, 19, 20 The high frequency of reported in 20/119 ALL cases (mostly children) including loss or acquisition of the common ALL antigen in 10 and four phenotypic switches hereby observed, suggests that this method may fail in predicting relapse in a proportion of cases, respectively, or more complicated sequential phenotypes in six cases. 2 A large study of the Pediatric Oncology patients with T-ALL. In studies of MRD with immunological methods, the use of several marker combinations may help to Group reported that shifts in childhood ALL (cases with a pre-B phenotype to early pre-B, or vice versa) occurred in about overcome problems related to such changes. The immunophenotypic pattern observed at 1st hematoloa third of cases. 5 In the same study, it was shown that the CD10 antigen can be either lost or acquired at relapse in gical relapse has been compared with the clinical outcome of the patients, in order to define features with potential prognos-23/161 non-T, non-B ALL. 5 In a small study of 10 cases, none of seven CD10-positive common ALL (six adults and one tic relevance. Our data confirm in adults what has been previously found in children: at 1st relapse, T lineage ALL has a child) modified the immunophenotype at relapse, with the
